Target Price | $5.10 |
Price | $2.41 |
Potential |
111.62%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Maravai LifeSciences 2026 .
The average Maravai LifeSciences target price is $5.10.
This is
111.62%
register free of charge
$13.86
475.10%
register free of charge
$2.02
16.18%
register free of charge
|
|
A rating was issued by 20 analysts: 11 Analysts recommend Maravai LifeSciences to buy, 8 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Maravai LifeSciences stock has an average upside potential 2026 of
111.62%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 259.19 | 198.76 |
10.30% | 23.31% | |
EBITDA Margin | -26.27% | -9.61% |
236.12% | 63.41% | |
Net Margin | -55.89% | -37.49% |
35.66% | 32.92% |
15 Analysts have issued a sales forecast Maravai LifeSciences 2025 . The average Maravai LifeSciences sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Maravai LifeSciences EBITDA forecast 2025. The average Maravai LifeSciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Maravai LifeSciences Analysts have issued a net profit forecast 2025. The average Maravai LifeSciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.05 | -0.29 |
16.67% | 72.38% | |
P/E | negative | |
EV/Sales | 3.37 |
15 Analysts have issued a Maravai LifeSciences forecast for earnings per share. The average Maravai LifeSciences EPS is
This results in the following potential growth metrics and future valuations:
Maravai LifeSciences...
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Locked
➜
Locked
|
Locked | May 13 2025 |
Craig-Hallum |
Locked
➜
Locked
|
Locked | May 13 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
UBS |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Baird |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
Analyst Rating | Date |
---|---|
Locked
Baird:
Locked
➜
Locked
|
May 13 2025 |
Locked
Craig-Hallum:
Locked
➜
Locked
|
May 13 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 25 2025 |
Locked
UBS:
Locked
➜
Locked
|
Mar 21 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Baird:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 05 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.